Skip to main content Skip to navigation
Human IFN-γ ELISA Set

Human IFN-γ ELISA Set

(RUO)
Human IFN-γ ELISA Set

This standard curve is for demonstration only. A standard curve must be run with each assay. Typical Standard Curve and 20-plate yield were obtained in the BD Biosciences Pharmingen laboratory, using the recommended procedure and manual plate washing.  

This standard curve is for demonstration only. A standard curve must be run with each assay. Typical Standard Curve and 20-plate yield were obtained in the BD Biosciences Pharmingen laboratory, using the recommended procedure and manual plate washing.  

Product Details
Down Arrow Up Arrow


BD OptEIA™
Human (QC Testing)
ELISA (Routinely Tested)
RUO
AB_2869029


Description

    Material Provided  

  

    The BD OptEIA™ Set for human interferon-gamma (IFN-γ), contains the components necessary to develop enzyme-linked immunosorbent assays (ELISA) for natural or recombinant human IFN-ã in serum, plasma, and cell culture supernatants. Sufficient materials are provided to yield approximately 20 plates of 96-wells if the recommended storage, materials, buffer preparation, and assay procedure are followed as specified in this package.  

  

  

  

    Assay Optimization  

  

    BD OptEIA™ Sets allow flexible assay design to fit individual laboratory needs. To design an immunoassay with different sensitivity and dynamic range, the following parameters can be varied: Capture, Detection Antibody titers, Incubation time, Incubation temperature, Assay Diluent formulation, Buffer pH, ionic strength, protein concentration, Type of substrate, Washing technique (i.e., number of wash repetitions and soak times).  

  

  

  

    Standardization: This immunoassay is calibrated against purified Baculovirus-expressed recombinant human IFN-γ produced at BD Biosciences Pharmingen.  

  

  

  

    The NIBSC/WHO First British Standard 82/587 (human IFN-γ prepared by induction of phytohaemagglutinin) was evaluated in this set. The conversion factor for NIBSC material is as follows: NIBSC equivalent value (IU/mL) = 0.010 x BD OptEIA™ human IFN-γ (pg/mL). The NIAID Standard #Gxg01-902-535 (recombinant human IFN-γ expressed in E. coli) was evaluated in this set. The converson factor for NIAID material is as follows: NIAID equivalent value (IU/mL) = 0.021 x BD OptEIA™ IFN-γ value (pg/mL).  

Preparation And Storage

Store unopened reagents at 2-8°C. do not use reagents after expiration date, or if turbidity is evident. Before use, bring all reagents to room temperature (18-25°C). Immediately after use, return to proper storage conditions. Lyophilized standards are stable until expiration date. After reconstitution, immediately aliquot standard stock in polypropylene vials at 50 µl per vial anf freeze at -80°C for up to 6 months. If necessary, store at 2-8°C for up to 8 hours prior to aliquotting/freezing. Do not leave reconstituted standard at room temperature.

Recommended Assay Procedures

    Recommended Buffers, Solutions  

  

    Note: Do not use sodium azide in these preparations. Sodium azide inactivates the horseradish peroxidase enzyme. The BD OptEIA™ Reagent Set B (Cat. No 550534) containing Coating Buffer, Assay Diluent, Substrate Reagents A and B, Stop Solution and 20X Wash Buffer Concentrate is recommended.  

  

    1. Coating Buffer - 0.1 M Sodium Carbonate, pH 9.5; 8.40 g NaHCO3, 3.56 g Na2CO3; q.s. to 1.0 L; pH to 9.5. Freshly prepare or use within 7 days of preparation, stored at 2-8°C.  

  

    2. Assay Diluent- PBS* with 10% FBS#, pH 7.0. The BD Pharmingen™ Assay Diluent (Cat. No. 555213) is recommended.  

  

    *Phosphate-Buffered Saline: 80.0 g NaCl, 11.6 g Na2HPO4, 2.0 g KH2PO4, 2.0 g KCl, q.s. to 10 L; pH to 7.0.  

  

    #Fetal Bovine Serum: Hyclone Cat. No. SH30088 (heat inactivated) recommended.  

  

    Freshly prepare or use within 3 days of preparation, with 2-8°C  storage.  

  

    3. Wash Buffer - PBS* with 0.05% Tween-20. Freshly prepare or use within 3 days of preparation, stored at 2-8°C.  

  

    4. Substrate Solution - Tetramethylbenzidine (TMB) and Hydrogen Peroxide. The BD Pharmingen™ TMB Substrate Reagent Set (Cat. No. 555214) is recommended.  

  

    5. Stop Solution - 1 M H3PO4 or 2 N H2SO4  

  

  

  

    Additional Materials Required  

  

    1. 96-well BD Falcon™ ELISA plates (Cat. No. 353279) are recommended  

  

    2. Microplate reader capable of measuring absorbance at 450 nm  

  

    3. Precision pipettes  

  

    4. Graduated cylinder, one liter  

  

    5. Deionized or distilled water  

  

    6. Wash bottle or automated washer  

  

    7. Log-log graph paper or automated data reduction  

  

    8. Tubes to prepare standard dilutions  

  

    9. Laboratory timer  

  

    10. Plate sealers or parafilm  

  

  

  

    Specimen Collection and Handling: Specimens should be clear, non-hemolyzed and non-lipemic.  

  

    Cell culture supernatants: Remove any particulate material by centrifugation and assay immediately or store samples at ≤ -20°C. Avoid repeated freeze-thaw cycles.  

  

    Serum: Use a serum separator tube and allow samples to clot for 30 minutes, then centrifuge for 10 minutes at 1000 x g. Remove serum and assay immediately or store samples at ≤ 20°C. Avoid repeated freeze-thaw cycles.  

  

    Plasma: Collect plasma using citrate, EDTA, or heparin as anticoagulant. Centrifuge for 10 minutes at 1000 x g within 30 minutes of  

  

    collection. Assay immediately or store samples at < -20°C. Avoid repeated freeze-thaw cycles.  

  

    Standards Preparation and Handling  

  

    1. Reconstitution: After warming lyophilized standard to room temperature, carefully open vial to avoid loss of material. Reconstitute lyophilized standard with 1.0 mL of deionized water to yield a stock standard. Allow the standard to equilibrate for at least 15 minutes before making dilutions. Vortex gently to mix.  

  

    2. Storage/ handling of reconstituted standard: After reconstitution, immediately aliquot standard stock in polypropylene vials at 50 µl per  

  

    vial and freeze at -80°C  for up to 6 months. If necessary, store at 2-8°C  for up to 8 hours prior to aliquotting/freezing. Do not leave reconstituted  

  

    standard at room temperature (RT).  

  

    3. Standards Preparation for Assay:  

  

    a. Prepare a 300 pg/mL standard from the stock standard. Vortex to mix. (See dilution instructions on Instruction/Analysis Certificate.)  

  

    b. Add 300 µL Assay Diluent to 6 tubes. Label as 150 pg/mL, 75 pg/mL, 37.5 pg/mL, 18.8 pg/mL, 9.4 pg/mL, and 4.7 pg/mL.  

  

    c. Perform serial dilutions by adding 300 µL of each standard to the next tube and vortexing between each transfer. Assay Diluent serves as  

  

    the zero standard (0 pg/mL).  

  

  

  

    Detailed Assay Procedure  

  

    1. Coat microwells with 100 µL per well of Capture Antibody diluted in Coating Buffer. For recommended antibody coating dilution, see lot-specific Instruction/Analysis Certificate. Seal plate and incubate overnight at 4°C.  

  

    2. Aspirate wells and wash 3 times with ≥ 300 μL/well Wash Buffer. After last wash, invert plate and blot on absorbent paper to remove any  

  

    residual buffer.  

  

    3. Block plates with ≥ 200 µL/well Assay Diluent. Incubate at room temperature (RT) for 1 hour.  

  

    4. Aspirate/wash as in step 2.  

  

    5. Prepare standard and sample dilutions in Assay Diluent. See "Standards Preparation and Handling".  

  

    6. Pipette 100 µL of each standard, sample, and control into appropriate wells. Seal plate and incubate for 2 hours at RT.  

  

    7. Aspirate/ wash as in step 2, but with 5 total washes.  

  

    8. Add 100 µL of Working Detector (Detection Antibody + SAv-HRP reagent) to each well. Seal plate and incubate for 1 hour at RT.  

  

    9. Aspirate/ wash as in step 2, but with 7 total washes. NOTE: In this final wash step, soak wells in wash buffer for 30 seconds to 1 minute  

  

    for each wash.  

  

    10. Add 100 µL of Substrate Solution to each well. Incubate plate (without plate sealer) for 30 minutes at RT in the dark.  

  

    11. Add 50 µL of Stop Solution to each well.  

  

    12. Read absorbance at 450 nm within 30 minutes of stopping reaction. If wavelength correction is available, subtract absorbance at 570 nm from absorbance 450 nm.  

  

  

  

    Assay Procedure Summary  

  

    1. Add 100 µL diluted Capture Ab to each well. Incubate overnight at 4°C.  

  

    2. Aspirate and wash 3 times.  

  

    3. Block plates: 200 µL Assay Diluent to each well. Incubate 1 hr RT  

  

    4. Aspirate and wash 3 times.  

  

    5. Add 100 µL standard or sample to each well. Incubate 2 hr RT.  

  

    6. Aspirate and wash 5 times.  

  

    7. Add 100 µL Working Detector (Detection Ab + SAv-HRP) to each well. Incubate 1 hr RT  

  

    8. Aspirate and wash 7 times (with 30 sec to 1 min soaks)  

  

    9. Add 100 µL Substrate Solution to each well. Incubate 30 min RT in dark  

  

    10. Add 50 µL Stop Solution to each well. Read at 450 nm within 30 min with λ correction 570 nm.  

  

  

  

    Calculation of Results  

  

    Calculate the mean absorbance for each set of duplicate standards, controls and samples. Subtract the mean zero standard absorbance from each.   

  

    Plot the standard curve on log-log graph paper, with IFN-γ concentration on the x-axis and absorbance on the y-axis. Draw the best fit curve through the standard points.  

  

    To determine the IFN-γ concentration of the unknowns, find the unknown's mean absorbance value on the y-axis and draw a horizontal line to the standard curve. At the point of intersection, draw a vertical line to the x-axis and read the IFN-γ concentration. If samples were diluted, multiply the IFN-γ concentration by the dilution factor.  

  

    Computer data reduction may also be employed, utilizing log-log regression analysis.  

  

  

  

    Specificity  

  

    Cross Reactivity: The following factors were tested in the BD OptEIA™ assay at ≥ 10 ng/mL and no cross-reactivity was identified.  

  

    Recombinant Human: IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12 (p40), IL-12 (p70), IL-13, IL-15, G-CSF, GM-CSF, CD23, Lymphotactin, MIP-1α, MIP-1β, MCP-1, MCP-2, NT-3, PDGF-AA, SCF, TNF, LT-α (TNF-β) VEGF  

  

    Recombinant Mouse: IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p70), IL-15, IFN-γ, GM-CSF, MCP-1, TCA3, TNF  

  

    Recombinant Rat: IL-2, IL-4, IL-6, IL-10, GM-CSF, IFN-γ, TNF  

  

    Other: Viral IL-10 (1 ng/mL) Rabbit TNF  

  

    Interfering Substances: The following substances at levels greater than or equal to 2 mg/ml were added to Assay Diluent spiked with 200 pg/mL IFNγ. No effect on assay results was observed. Bilirubin, Human γ-globulin, Human hemoglobin, Human serum albumin, Human transferrin, Triglycerides, Herparin (300 units/mL), Sodium Citrate, EDTA.  

  

  

  

    Limitations of the Procedure  

  

    · Samples that generate absorbance values higher than the standard curve should be diluted with Standard Diluent and re-assayed.  

  

    · Interference by drug metabolites, soluble receptors, or other binding proteins in specimens has not been thoroughly investigated. The possibility of interference cannot be excluded.  

  

    · BD OptEIA™ Sets are intended for use as an integral unit. Do not mix reagents from different Set batches. Reagents from other manufacturers are not recommended for use in this Set.  

Product Notices

  1. For online training for BD OptEIA™ Set ELISA Techniques, please refer to http://www.bdbiosciences.com/OptEIA/downloads.shtml
  2. Samples that generate absorbance values higher than the standard curve should be diluted with Standard Diluent and re-assayed.
  3. Interference by drug metabolites, soluble receptors, or other binding proteins in specimens has not been thoroughly investigated. The possibility of interference cannot be excluded.
  4. BD OptEIA™ Sets are intended for use as an integral unit. Do not mix reagents from different Set batches. Reagents from other manufacturers are not recommended for use in this Set.
  5. Reagents which contain preservatives may be toxic if ingested, inhaled, or in contact with skin.
  6. Handle all serum and plasma specimens in accordance with NCCLS guidelines for preventing transmission of blood-borne infections.
  7. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  8. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
  9. ProClin is a trademark of Rohm and Haas Company.
555142 Rev. 1
Components
Down Arrow Up Arrow
Description Quantity/Size Part Number
Capture Antibody Purified Anti-Human IFN-γ N/A 51-26131E
Detection Antibody Biotin Anti-Human IFN-γ N/A 51-26132E
Recombinant Human IFN-γ Lyophilized Standard N/A 51-26136E
Streptavidin-horseradish peroxidase conjugate (SAv-HRP) N/A 51-9002208
555142 Rev. 1
Citations & References
Down Arrow Up Arrow

Development References (6)

  1. Salih HR, Kosowski SG, Haluska VF, et al. Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells.. J Immunol. 2000; 165(5):2903-2910. (Biology). View Reference
  2. Salih HR, et al. Constitutive Expression of Functional 4-1 BB (CD 137) Ligand on Carcinoma Cells. J Immunol. 2000; 165(5):2903–2910. (Biology).
  3. Sester U, Sester M, Hauk M, Kaul H, Köhler H, Girndt M. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients.. Nephrol Dial Transplant. 2000; 15(8):1217-1223. (Biology). View Reference
  4. Sester U, et al. T-cell Activation Follows Th1 Rather than Th2 Pattern in Haemodialysis Patients. Nephrology Dialysis Transplantation. 2000; 15:1217–1223. (Biology).
  5. Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming.. Nat Med. 2001; 7(3):297-303. (Biology). View Reference
  6. Wolfers J, et al. Tumor-Derived Exosomes are a Source of Shared Tumor Rejection Antigens for CTL Cross-Priming. Nature Medicine. 2001; 9(3):297-303. (Biology).
View All (6) View Less
555142 Rev. 1

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

Non-IVD products are For Research Use Only. Not for use in diagnostic or therapeutic procedures.

 

23-22940-00